Abstract 1687
Background
Although Brazilian publications on BRCA mutations predisposing to breast/ovarian cancer have increased in the last five years, the genetic Background of this population is still underrepresented. Mostly, screening has been performed in patients from south-southeast states who met the NCCN guidelines. We present a cohort of breast/ovarian cancer patients, in a private laboratory with a wide market capillarity, where a subset of patients without strict criteria may have access to the test on medical request.
Methods
A total of 1,284 consecutive patients were referred for molecular screening to a private laboratory between January 2017-March 2019. Next-generation sequencing and multiplex ligation-dependent probe amplification (MLPA) for BRCA1/2 genes were performed for all patients, except for 15 that were evaluated only by MLPA. Bioinformatic tools with specific algorithms for variant calling and annotation were employed.
Results
Pathogenic germline variants were identified in 12% (n = 156) of patients: 61% in BRCA1 and 39% in BRCA2. To our knowledge, 25 BRCA2 and 17 BRCA1 germline mutations have not been previously described in Brazilian reports. Frameshift and nonsense alterations were the most prevalent types (52% and 22%, respectively). While sixty non-recurring mutations were identified, 31 in BRCA1 and 29 in BRCA2, eleven pathogenic variants were detected 3 or more times, 7 BRCA1 and 4 BRCA2. In agreement with previous reports, c.5266dupC, c.3331_3334delCAAG (BRCA1) and c.2808_2811delACAA (BRCA2) were the most frequent variants. One large rearrangement (deletion of exons 15-16) and the Portuguese founder Alu insertion, c.156_157insAlu, both in BRCA2, were also detected. Additionally, three BRCA1 (c.5074 + 1delG; c.131_132delGC; c. 4414delC) and five BRCA2 (c.6407T>G, c.3659dupA, c.3601_3602delinsT, c.8682delA; c.4329delT) novel mutations were observed.
Conclusions
Our results confirm the reported molecular heterogeneity of Brazilian patients, highlighting the identification of 8 germline pathogenic variants not yet described in BRCA 1/2 reference databases. The detected mutations were associated to a vast array of ethnicities, confirming the admixture of Brazilian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2670 - Molecular subtypes of metastatic(met) gastric cancer(GC) (MoTriGastric): new biomarkers closer to the clinics
Presenter: Maria Alsina Maqueda
Session: Poster Display session 2
Resources:
Abstract
3797 - Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
Presenter: Aafke Creemers
Session: Poster Display session 2
Resources:
Abstract
5485 - Clinical implication of CLDN18, RhoGAP, and E-cadherin in gastric signet ring cell carcinoma
Presenter: Hyunho Kim
Session: Poster Display session 2
Resources:
Abstract
1970 - Identification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing.
Presenter: IRINA EFIMOVA
Session: Poster Display session 2
Resources:
Abstract
4989 - The molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients
Presenter: Jia Wei
Session: Poster Display session 2
Resources:
Abstract
7145 - A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Presenter: Alison Schram
Session: Poster Display session 2
Resources:
Abstract
1406 - Simultaneous Resection of Pancreatic Cancer and Liver Oligometastases After Induction Chemotherapy in Stage IV Patients:an Open-Label Prospective Randomized Multicenter phase 3 trial(CSPAC-1)
Presenter: Miaoyan Wei
Session: Poster Display session 2
Resources:
Abstract
1530 - Multicenter randomized phase II trial of 5-Fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
Presenter: Changhoon Yoo
Session: Poster Display session 2
Resources:
Abstract
1563 - A randomized phase II study of Maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced Pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)
Presenter: Cindy Neuzillet
Session: Poster Display session 2
Resources:
Abstract
2780 - A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Presenter: Do-Youn Oh
Session: Poster Display session 2
Resources:
Abstract